# To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Study · id `cardio:ct-nct05852431` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05852431](<https://clinicaltrials.gov/study/NCT05852431>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05852431

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 369 participants.

## Technical summary

Registry record NCT05852431. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-15 (actual); primary completion 2025-07-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 369 participants (enrolled count; ClinicalTrials.gov record NCT05852431, source copy `cardio:ctgov-nct05852431-2026-07-07`, retrieved 2026-10-31)
- Started: 2023-06-15 (actual) (ClinicalTrials.gov record NCT05852431, source copy `cardio:ctgov-nct05852431-2026-07-07`, retrieved 2026-10-31)
- Primary completion: 2025-07-07 (actual) (ClinicalTrials.gov record NCT05852431, source copy `cardio:ctgov-nct05852431-2026-07-07`, retrieved 2026-10-31)
- Completion: 2026-04-09 (actual) (ClinicalTrials.gov record NCT05852431, source copy `cardio:ctgov-nct05852431-2026-07-07`, retrieved 2026-10-31)
- Countries: United States; Argentina; Austria; Belgium; Bulgaria; Canada; Chile; Czechia; France; Georgia; Germany; Hungary; India; Italy; Latvia; Mexico; Poland; Puerto Rico; Spain; United Kingdom (ClinicalTrials.gov record NCT05852431, source copy `cardio:ctgov-nct05852431-2026-07-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05852431-2026-07-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
- Acronym: ENTRUST
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): Pegozafermin
- Intervention (Drug): Placebo
- Lead sponsor: 89bio, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)

## Provenance

Content hash: 0e09e6f365423cf33e4f47ed4d4f8efaec7cbe28c756d8ca26b843bba43de3c1
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
